EUVIMEDEUVIMED entdecken
Crossref

Peritransplant lysine methyltransferase 2a–rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia

Lu-Lu Wang, Peng Zhao, Jing Liu, Zhuo-Yu An, Hai-Xia Fu, Chen-Cong Wang, Meng Lv, Chen-Hua Yan, Ting-Ting Han, Yu-Hong Chen, Jun Kong, Yuan-Yuan Zhang und 13 weitere

Cancer · 2025

DOI: 10.1002/cncr.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Lu-Lu Wang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Histone-Lysine N-Methyltransferase, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 63 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Key Program of the National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study examined the impact of measurable residual disease (MRD) dynamics in adults with lysine methyltransferase 2a rearrangement ( KMT2A r) in acute myeloid leukemia (AML) during the peritransplant period (before and early after allogeneic hematopoietic stem cell transplantation [HSCT]).

Methods

This study involved 144 adult patients with AML with KMT2A r who underwent HSCT between 2015 and 2024. Patients were enrolled if they survived without relapse for at least 3 months post‐HSCT. MRD was measured via real‐time quantitative polymerase chain reaction.

Results

The cohort was categorized into four groups on the basis of MRD status before and after HSCT, respectively: MRD negative/MRD negative ( n = 81), MRD negative/MRD positive ( n = 2), MRD positive/MRD negative ( n = 43), and MRD positive/MRD positive ( n = 18). Significant differences were found in 3‐year overall survival (OS), leukemia‐free survival (LFS), and cumulative incidence of relapse (CIR) (all p < .001), with the MRD‐negative/MRD‐negative group having the best outcomes (88% OS, 85% LFS, and 10% CIR), whereas the MRD‐negative/MRD‐positive group (0% OS, 0% LFS, and 100% CIR) and MRD‐positive/MRD‐positive group (29% OS, 31% LFS, and 69% CIR) had the worst outcomes. The MRD‐positive/MRD‐negative group had an intermediate prognosis (63% OS, 58% LFS, and 32% CIR). Peri‐HSCT MRD dynamics served as an independent factor, which distinguished patient groups with differential risk probabilities of mortality and relapse. C ‐statistic values were greater when peri‐HSCT MRD dynamic testing was used than when isolated pre‐ or post‐HSCT MRD was used to predict CIR (0.68 vs. 0.58 vs. 0.56), LFS (0.74 vs. 0.69 vs. 0.64), and OS (0.73 vs. 0.68 vs. 0.66).

Conclusions

Compared with single–time point MRD assessments, peritransplant MRD dynamics confer superior prognostic accuracy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualLeukemia, Myeloid, AcuteHistone-Lysine N-MethyltransferaseHematopoietic Stem Cell TransplantationHumansFemaleMaleAdultMiddle AgedPrognosisYoung AdultAgedGene RearrangementAdolescentBiomarkers, TumorMyeloid-Lymphoid Leukemia Protein

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic hematopoietic stem cell transplantationdynamicslysine methyltransferase 2a (KMT2A)measurable residual disease

Substanzen

Histone-Lysine N-MethyltransferaseBiomarkers, TumorKMT2A protein, humanMyeloid-Lymphoid Leukemia Protein

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.

ORCID-Profile: Xiao-Hui Zhang

Förderung

  • National Key Research and Development Program of China
  • Key Program of the National Natural Science Foundation of China
  • Beijing Municipal Natural Science Foundation
  • Beijing Tongzhou Science and Technology Foundation

Zitieren

APA

Wang, L. L., Zhao, P., Liu, J., An, Z. Y., Fu, H. X., Wang, C. C., Lv, M., Yan, C. H., Han, T. T., Chen, Y. H., Kong, J., Zhang, Y. Y., Chen, Y., Wang, Z. D., Han, W., He, Y., Mo, X. D., Wang, F. R., Wang, J. Z., …, & Zhang, X. H. (2025). Peritransplant lysine methyltransferase 2a–rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia. Cancer. https://doi.org/10.1002/cncr.70044

Vancouver

Wang LL, Zhao P, Liu J, An ZY, Fu HX, Wang CC, et al. Peritransplant lysine methyltransferase 2a–rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia. Cancer. 2025. doi:10.1002/cncr.70044

BibTeX
@article{Wang2025,
  author = {Wang, Lu-Lu and Zhao, Peng and Liu, Jing and An, Zhuo-Yu and Fu, Hai-Xia and Wang, Chen-Cong and Lv, Meng and Yan, Chen-Hua and Han, Ting-Ting and Chen, Yu-Hong and Kong, Jun and Zhang, Yuan-Yuan and Chen, Yao and Wang, Zhi-Dong and Han, Wei and He, Yun and Mo, Xiao-Dong and Wang, Feng-Rong and Wang, Jing-Zhi and Chang, Ying-Jun and Zhao, Xiang-Yu and Wang, Yu and Xu, Lan-Ping and Huang, Xiao-Jun and Zhang, Xiao-Hui},
  title = {Peritransplant lysine methyltransferase 2a–rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70044}
}
Kostenlos starten →